Diamyd Medical meets study goal with diabetes vaccine
A vaccine candidate for diabetes, Diamyd, has met its primary endpoint in a phase II study, with 14 participants remaining insulin-independent 12 months after first injection.
by christian bundgaard, translated by daniel pedersen
A clinical phase II trial of diabetes vaccine candidate Diamyd has shown positive topline results, the vaccine’s developer Diamyd Medical reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
